Data from The mRNA-Based Therapeutic Vaccine NTX250 Induces Potent Antitumor Immunity in HPV-Driven Cancers
Year: 2026
Type: other
Abstract: Human papillomavirus (HPV) plays a pivotal role in various malignancies, including cervical, anogenital, head, and neck cancers. Despite the availability of highly effective prophylactic vaccines, many individuals remain susceptible to HPV-driven cancers because of barriers such as limited vaccine access, lack of awareness, or personal preferences. Current treatments primarily target lesions without eradicating persistent HPV infections, leading to an increased risk of subsequent HPV-associated cancers. This scenario underscores an urgent need for innovative treatment modalities aimed at eliminating persistent HPV infections. In this study, we developed NTX250, a messenger RNA (mRNA)–based therapeutic platform engineered to deliver HPV type 16 (HPV16) E6 and E7 antigens, in conjunction with the immunomodulators interleukin (IL) 12 and LIGHT. A lipid and ionizable peptoid nanoparticle system facilitated precise intralesional delivery of NTX250. Localized NTX250 administration in HPV16-transformed tumor-bearing models led to complete tumor regression and established durable, antigen-specific immune memory. Replacing the HPV antigens with a construct comprising colorectal cancer cell–specific neoepitopes enabled stimulated antitumor immunity and suppressed tumor growth, supporting the generalizability of the approach. Overall, NTX250 represents a promising nonsurgical immunotherapy platform that is capable of eliciting robust and targeted antitumor immune responses across diverse malignancies. This adaptable mRNA nanoparticle approach enables the codelivery of tumor-specific antigens and immunomodulators, with the potential to target tumor-associated antigens beyond HPV. Significance: NTX250 is an mRNA-based therapeutic platform that offers a noninvasive approach to eradicate persistent HPV infections and induce strong antitumor immune responses, fulfilling a critical need in HPV-related cancer treatment.
Authors: Meredith Leong, Weiqun Liu, Nicole Fay, Diane M. Da Silva, Ou Li, Chris S. Rae, Adrienne Sallets, Ruben Prins, Daniel O. Frimannsson, Colin J. McKinlay, Ray Low, Daniel J. Fernandez, Gunasekaran Kannan, Pragyesh Dhungel, Sangeeta Nath, Nicole E. Peck, Elizabeth R. Webster, Ximiao Wen, Anushtha Sharma, Edward E. Lemmens, Evan McCartney-Melstad, Samuel Deutsch, W. Martin Kast, Ole Audun Werner Haabeth
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7234534317
Cites:
Cited by:
Related to:
